Study of CS-3150 in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1001 participants.
Also called NCT02890173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,001 participants
- Sponsor
- Registry
-
NCT02890173
-
- Other papers using this trial's data
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02890173. Randomized; quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-07-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of CS-3150 in Patients With Essential Hypertension
- Acronym
- ESAX-HTN
- Condition
- Essential Hypertension
- Intervention (Drug)
- CS-3150
- Intervention (Drug)
- Eplerenone
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
Record details
- Record id
cardio:ct-nct02890173- Content hash
a6b537bd556b4b6f3f88445f5b875ab5cb60986f854b96423a6c65a97183d5b0